Channel Fragmentation and Diversifying Product Archetypes (with abstract)
| Channel Fragmentation and Diversifying Product Archetypes (with abstract) | |
|---|---|
| Published By | [[Pharmaceutical commerce]] |
| Publish Date | June, 2023 |
| Authors | William Roth |
| Topics | B2B eCommerce in Pharma |
| Statistics | |
| Article Size | words |
| Diagrams | No |
| Downloadable Version | No |
| Reviewers | |
| Page Owner | Nikolay Sidelnikov |
| Summary Author | Nikolay Sidelnikov |
Abstract
The article Channel Fragmentation and Diversifying Product Archetypes was published by Pharmaceutical Commerce in 2023. The text by industry expert William Roth describes the dramatic changes that happens in the pharmaceutical industry already now (precision medicines, such as cell and gene therapies and orphan and rare drugs).
Even though the digital commerce topic is not in the focus of this article, it is easy to mention, that building new digital-native business models would be the most (and probably the only) efficient way of reacting the to these industry specific challenges.
The article describes some key trends that happens in the industry and points that many new products don't fit into the decaying legacy payer, pharmacy, and distribution models that formed in the 1980s and '90s.
The author explains in details how change of product archetypes on the market leads to breaking traditional business models on retail level and then across the whole value chain. This thesis is illustrated with some examples from the past that demonstrate how different archetypes changed the game since 1990s.
The text is continued with the analysis of current situation. Using the example of "specialty lite" products priced between $5,000 and $25,000 annually the author demonstrate the issue with the current distribution model, pointing that e-commerce and digital pharmacies may solve it while some industry specific challenges exists in that area too.
The conclusion is that each product archetype means a dedicated business model abd these models are rarely to be the same. The implication for the industry is the fast growing complexity, which is the new norm for the pharmaceuticals market. That means that pharmaceutical companies should be ready rapidly change or build new business models on a regular basis.
Some recommendations are listed at the last part of the article.
The author highlights that for the last two to three decades, pharma manufacturers have operated in commercial silos with marketing, field sales, payer and market access, channel and distribution, and patient support services operating as separate business. The situation should be changed because "models that show product simply moving from a third-party logistics provider (3PL) to a wholesaler, to a pharmacy, and to a patient with payer coverage and happy providers are only true for a small and shrinking portion of the market".
Full article: Channel Fragmentation and Diversifying Product Archetypes